Major League Baseball (MLB) and the Major League Baseball Players Association (MLBPA) today released the annual public report from the Joint Drug Prevention and Treatment Program’s Independent Program Administrator. The Joint Drug Prevention and Treatment Program calls for a public report to be issued each year.
The accompanying report from the Independent Program Administrator, Thomas M. Martin, Ph.D., covers the period from the beginning of the 2023-2024 off-season through the end of Major League Baseball’s 2024 Postseason.
2024 Public Report of Major League Baseball’s Joint Drug Prevention and Treatment Program
This report covers the time from the beginning of the 2023-2024 off-season to the end of the 2024 Postseason (the “2024 Reporting Period”). As per agreement between the Office of the Commissioner of Baseball and the Major League Baseball Players Association, the following report is specific to Players on the 40-man rosters for Major League Baseball Clubs.
- The total number of drug tests that were conducted during the 2024 Reporting Period was 11,609. Of this total number, 9,455 were urine samples that were collected and analyzed for Performance Enhancing Substances, Stimulants, DHEA, Diuretics, Masking Agents, and Drugs of Abuse. The number of blood samples that were collected and analyzed for the presence of human growth hormone (hGH) was 2,154.
- Two (2) adverse analytical findings were reported by the UCLA Laboratory and resulted in discipline. These findings were for the following Performance Enhancing Substances:
Boldenone
Clomiphene
- Sixty-five (65) Therapeutic Use Exemptions were granted. The diagnoses were as follows:
Attention Deficit Hyperactivity Disorder: 61
Altitude sickness: 1
Hormone function: 1
Hypertension: 1
Sleep disorder: 1
